Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE. Show more
3060 Pegasus Park Drive, Dallas, TX, 75247, United States
Market Cap
1.634B
52 Wk Range
$10.11 - $77.20
Previous Close
$76.99
Open
$76.99
Volume
N/A
Day Range
$76.99 - $76.99
Enterprise Value
1.436B
Cash
58.22M
Avg Qtr Burn
-18.81M
Insider Ownership
2.06%
Institutional Own.
96.65%
Qtr Updated
03/31/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
FB102 Details Celiac Disease | Phase 2 Data readout | |
FB102 (Anti-CD122 Antibody) Details Vitiligo | Phase 1b Data readout | |
FB102 (Anti-CD122 Antibody) Details Alopecia Areata | Phase 1b Data readout | |
FB102 Details Graft-versus-host disease | Phase 1 Data readout |